Skip to main content

Wall Street is ditching amyloid-based Alzheimer’s drugs. They shouldn't, scientists say

Wall Street analysts, reacting to a string of Alzheimer’s drug failures, are telling investors that it’s time to ditch amyloid-based treatments. But scientists don’t agree.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.